These receptors are mainly expressed in neuronal tissue and have critical role in cell differentiation, survival, and proliferation.
Global TRK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global TRK Inhibitors Market Opportunity Assessment: > USD 2 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 Drugs (Vitrakvi & Rozlytrek)
- Approved TRK Drug Patent, Price & Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
https://www.kuickresearch.com/report-trk-inhibitors-market-size-sales-growth-forecast
The neurotropic tyrosine receptor kinase (NTRK) genes NTRK1, NTRK2, and NTRK3 encode the tropomyosin receptor kinase (TRK) family of proteins: TRKA, TRKB, and TRKC, respectively. These receptors are mainly expressed in neuronal tissue and have critical role in cell differentiation, survival, and proliferation. Further, genomic analyses have revealed that NTRK gene fusions have role in driving several cancers in both adults and pediatric patients. Their potential role in the development of cancer has led to discovery of several TRK inhibitors as an alternate approach to target cancer.
Currently, two TRK inhibitors including Vitrakvi (larotrectinib) and Rozlytrek (entrectinib) have gained entry in to the market. Vitrakvi developed by Loxo Oncology is approved in more than 40 countries for the management of adult and pediatric patients of all ages with TRK fusion cancer. It is selective and potent inhibitor of TRKA, TRKB, and TRKC. In contract, entrectinib is a multikinase inhibitor that targets TRK, ALK, ROS1, and JAK which is approved in US and Europe for management adult and pediatric patients 12 years or older with locally advanced or metastatic TRK fusion cancer. Apart from this, researchers have also developed several next generation TRK inhibitors to address on-target resistance that is mediated by first generation TRK inhibitors. The most advanced agents, selitrectinib and repotrectinib, are in phase I/II development, and preliminary data suggest encouraging clinical activity.
The advent of TRK inhibitor in the management of cancer has greatly transformed the cancer therapeutics market. In a short span of time, TRK inhibitory drugs have contributed to a significant share in the cancer therapeutics market owing to their high specificity and target ability towards cancer cell. Unlike conventional cancer therapies, the novel class of TRK inhibitors is not associated with any adverse side-effects and does not hamper the quality of life of patients, which further propel the growth of market. Moreover, there will no competition from generic drugs during the forecast period, which further boost their sales at a global level, thus driving the growth of market.
The accelerated sales of the drug and the significant advantages have drawn the attention of several researchers and pharmaceutical companies to invest in this sector. The extensive efforts by the researchers and the rising collaboration among the pharmaceutical giants are expected to drive the future of the market in coming years. For instance in May, 2021 AUM Biosciences have entered into strategic collaboration with Handok Inc. and CMG Pharmaceutical for the worldwide (excluding Korea) development, commercialization, and manufacturing rights of CHC2014, which is highly specific and efficacious pan-TRK inhibitor. The other key players in the market include Novartis, Loxo Oncology, Roche, Aum Biosciences, Turning Point Therapeutics, InnoCare, and others.
As per our report findings, the global TRK inhibitor market will surpass US$ XX Billion by 2028. The increase in prevalence of NTRK positive cancers is expected to fuel the TRK inhibitor market. Apart from this, continuous clinical trials and studies on TRK inhibitors as a new treatment in the field of oncology is expected to propel the market during the forecast period. In addition, their limited adverse effects and higher efficiency of TRK inhibitors will also increase their demand in the market.
The report provides comprehensive analysis on the availability of TRK inhibitors, pricing, dosage, and sales analysis. In addition, deep insights into ongoing clinical trials in global market and key drugs in research and development are also mentioned in the report. On the basis of region, the report has been segmented into US, Europe, Japan, and rest of world whereas by therapeutic indication, it is segmented into lung cancer, breast cancer, colorectal cancer, glioblastoma, and thyroid cancer.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366